Iressa is comparable to docetaxel in survival rate

Published: 2007-09-10 06:57:00

Updated: 2007-09-10 06:57:00

AstraZeneca Korea said on September 5 that patients with non-small cell lung cancer (NSCLC) treated with the oral anti-cancer drug Iressa (gefitinib) in the INTEREST study had equivalent (non-inferior) survival to those treated with intravenous docetaxel, citing data presented at the World Conference on Lung Cancer in Korea.

The company also added that Iressa demonstrated a more favorable to...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.